Mycology

Bridgetown Mushrooms Proudly Partners with RPG Coffee and Kindness.org to Launch Kind Coffee Cooperative™— Promoting Wellness and Fostering Kindness

Retrieved on: 
Wednesday, April 24, 2024
Coffee, Sale, Pacific Northwest, Nature, Partnership, Aloe, Research, IBN, Science, Mycology, Festival International, RPG, Human

The cooperative is a fusion of exceptional coffee craftsmanship and the healing power of nature, featuring RPG Coffee's expertise in coffee blending, Bridgetown Mushrooms' organic lion’s mane mushrooms, and the benefits of aloe.

Key Points: 
  • The cooperative is a fusion of exceptional coffee craftsmanship and the healing power of nature, featuring RPG Coffee's expertise in coffee blending, Bridgetown Mushrooms' organic lion’s mane mushrooms, and the benefits of aloe.
  • Chris Capozzoli, CEO of RPG Coffee, shared his perspective: "Our collaboration with Bridgetown Mushrooms, incorporating their lion’s mane mushrooms into our coffee and structured aloe is more than just innovative—it’s transformative.
  • Real People Giving (RPG) Coffee is a distinguished, veteran-owned and operated enterprise that is making waves in the wellness industry.
  • Specializing in the development of whole food ingredients-based supplements and exceptional coffee, RPG Coffee exemplifies a deep-rooted commitment to giving back.

BIOHM Health Inc. Partners with Virginia Tech to Accelerate Bacterial and Fungal Microbiome-Based Product Development and Commercialization through A.I.

Retrieved on: 
Thursday, March 7, 2024
Senior, Research, Intelligence, Dietary supplement, Health, Medical Mycology, Mycology, Dysbiosis, Data, Bacteria, Biomarker, Metadata, Case Western Reserve University, Longevity, Machine learning, Publication, A.I, Partnership

BIOHM's dataset, one of the largest in the world, combines bacterial and fungal genetic sequencing with over 50 metadata points.

Key Points: 
  • BIOHM's dataset, one of the largest in the world, combines bacterial and fungal genetic sequencing with over 50 metadata points.
  • This collaboration marks a significant step forward in the development and commercialization of condition specific dietary supplements based on a more complete understanding of the microbiome.
  • BIOHM Health Inc. is renowned for its groundbreaking work in microbiome research, leveraging its dataset to develop the next generation of targeted microbiome-based products.
  • The partnership between BIOHM Health Inc. and Virginia Tech represents a collaborative effort to push the boundaries of microbiome research and product development.

Napp announces authorisation of REZZAYO® (rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis in adults1

Retrieved on: 
Friday, February 2, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Multimedia, Hypokalemia, Tremor, Mortality, Mycology, Immunodeficiency, Hospice and palliative medicine, Nausea, MHRA, Immune system, UV, Candidiasis, Anemia, Caspofungin, Disease, Wheeze, Patient, Safety, DRC, Abdominal pain, Flushing, Diagnosis, Erythema, Hyponatremia, Rash, Sensation, Royal College of Pathologists, Radiation, Hypotension, Constipation, Risk, Vomiting, Restore, Medication, Phototoxicity, Infection, Medicine, Common, ODD, Diarrhea, Mitt, Pharmaceutical industry

Napp Pharmaceuticals Limited, a member of the international network of Mundipharma independent associated companies, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised rezafungin for the treatment of invasive candidiasis in adults in Great Britain (GB).1,2

Key Points: 
  • Napp Pharmaceuticals Limited, a member of the international network of Mundipharma independent associated companies, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised rezafungin for the treatment of invasive candidiasis in adults in Great Britain (GB).1,2
    This press release features multimedia.
  • Common adverse reactions include anaemia, hypomagnesaemia, hypophosphataemia, hypotension, wheezing, vomiting, nausea, abdominal pain, constipation, erythema, and rash.
  • Increased blood alkaline phosphatase, hepatic enzymes, alanine aminotransferase, aspartate aminotransferase and blood bilirubin were also common.
  • Transient infusion-related reactions have occurred with rezafungin, characterised by flushing, sensation of warmth, nausea, and chest tightness.2
    Rezafungin may cause increased risk of phototoxicity.

Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

Retrieved on: 
Friday, December 22, 2023
Phase, European Commission, Caspofungin, Medical Mycology, Immune system, EMA, Candidiasis, Disease, Mortality, European, SAN, Civil service commission, CDTX, Therapy, European Medicines Agency, Committee, Patient, Collaboration, Mycology, CHMP, Pharmaceutical industry

REZZAYO represents the first new treatment option in over 15 years for patients with invasive candidiasis.

Key Points: 
  • REZZAYO represents the first new treatment option in over 15 years for patients with invasive candidiasis.
  • Cidara is entitled to receive a milestone payment of approximately $11.14 million from Mundipharma for the European Medicines Agency (EMA) approval.
  • SAN DIEGO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced REZZAYO (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults.
  • Cidara Therapeutics has partnered with Mundipharma, which has commercial rights to rezafungin outside the U.S. and Japan.

Mundipharma announces European approval of REZZAYO® (rezafungin) for the treatment of Invasive Candidiasis in adults

Retrieved on: 
Friday, December 22, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Phase, European Commission, Caspofungin, Medical Mycology, Immune system, Medicine, Disease, Mortality, European, Civil service commission, Candidiasis, Committee, Patient, Mycology, Infection, CHMP

Mundipharma today announced rezafungin (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults.

Key Points: 
  • Mundipharma today announced rezafungin (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults.
  • Today’s announcement by the European Commission marks an important moment that could enable the healthcare professional community to manage invasive candidiasis patients in a different way using a new treatment option.”
    “The European approval is a culmination of years of developing an additional treatment option for invasive candidiasis patients and underscores our commitment to supporting management of infectious diseases,” said Yuri Martina, Chief Development and Medical Officer at Mundipharma.
  • *To meet the pre-specified limit of non-inferiority, the upper (for all-cause mortality) and lower (for global cure) 95% confidence limits for the difference between arms must be within 20%.
  • Both endpoints met the pre-specified 20% limit, establishing non-inferiority.1

PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide

Retrieved on: 
Tuesday, November 7, 2023
WHO, FDA, MDMA, Radioisotope Production Facility, Psilocybin, Mycology, Prohibition of drugs, EMA, Psilocybe, Safety, License, General counsel, Pharmaceutical industry

The Company is current growing weekly with authorization to store up to 250,000 kg of dried psilocybin-containing mushrooms on-site, or the equivalent of 1,250 kg of psilocybin.

Key Points: 
  • The Company is current growing weekly with authorization to store up to 250,000 kg of dried psilocybin-containing mushrooms on-site, or the equivalent of 1,250 kg of psilocybin.
  • PurMinds™ is currently able to supply its psilocybin mushrooms in dried whole mushroom form, or milled and encapsulated, with potency analyses reaching average total tryptamine levels of up to 1.03%.
  • To support patient safety and practitioner confidence, each batch is also tested for impurities.
  • "The specialized expertise that our scientists and cultivation team possess, coupled with the Company's strong focus on safety, efficacy and profitability, has ideally positioned PurMinds to be at the forefront of legal natural psilocybin mushroom supply."

Microdose Presents: Growing 'Happy Mushrooms' at Home with Curative Mushrooms

Retrieved on: 
Wednesday, November 1, 2023
Human, Mental health, Mycology, Education, Health, Nightclub, Fungiculture, Microdosing

Titled "Wonderland" the event aims to shine a light on the potential of psychedelics to revolutionize mental health and wellness.

Key Points: 
  • Titled "Wonderland" the event aims to shine a light on the potential of psychedelics to revolutionize mental health and wellness.
  • Curative Mushrooms, known for their innovative approach to mushroom cultivation, will lead an engaging session on growing 'Happy Mushrooms' at home for beginners.
  • “We are honored to have Curative Mushrooms join us,” said Leah Good, Operations Director of Microdose.
  • “It’s a privilege to be part of this event and share our passion for mushrooms with the Microdose community,” said Oliver Carlin, Founder of Curative Mushrooms.

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Retrieved on: 
Tuesday, October 24, 2023
Yeast, TIMM, European Confederation, IV, Antimalarial medication, Auris, Candida albicans, Biotechnology, Congress, Professor, ECMM, Mouse, Candida auris, University of Graz, University, Medical Mycology, Fungal infection, Patient, Associate, Mycology, Pharmaceutical industry

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.

Key Points: 
  • JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.
  • “We are excited to see the progress in the development of this novel compound from the fungerp family,” said Dr. Martin Hoenigl, FECMM, Associate Professor of Translational Mycology at University of Graz, Austria and president of the European Confederation of Medical Mycology (ECMM).
  • Results illustrated the potent and broad-spectrum in vitro activity of SCY-247, including against a large array of yeasts, molds and dimorphic fungi.
  • Results also demonstrated SCY-247’s extensive tissue distribution in mice, including brain penetration.

GrowLife Announces the Release of Kind Coffee Co-Op™ in Collaboration with RPG Coffee and Kindness.org

Retrieved on: 
Monday, October 16, 2023
Partnership, OTC, Coffee, Mycology, Human, IBN, RPG, Science, Pacific Northwest, Agaricus bisporus, Research, Sale, Medicinal plants, Fungiculture

PORTLAND, Ore., Oct. 16, 2023 (GLOBE NEWSWIRE) -- via IBN – GrowLife, Inc. (OTC: PHOT) (“GrowLife” or the “Company) is pleased to announce the release of its newest product, Kind Coffee Cooperative™.

Key Points: 
  • PORTLAND, Ore., Oct. 16, 2023 (GLOBE NEWSWIRE) -- via IBN – GrowLife, Inc. (OTC: PHOT) (“GrowLife” or the “Company) is pleased to announce the release of its newest product, Kind Coffee Cooperative™.
  • Kind Coffee Co-Op is a purpose-driven collaboration organized to foster kindness to the body, global community and Mother Earth.
  • Real People Giving (RPG) Coffee is a distinguished, veteran-owned and operated enterprise that is making waves in the wellness industry.
  • Specializing in the development of whole food ingredients-based supplements and exceptional coffee, RPG Coffee exemplifies a deep-rooted commitment to giving back.

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

Retrieved on: 
Friday, October 13, 2023
European, Infection, Restore, Committee for Medicinal Products for Human Use, CHMP, Fungal infection, European Medicines Agency, DFC, CDTX, Mortality, European Commission, Tavarua, Safety, Disease, EMA, Medical Mycology, FDA, Therapy, Phase, EC, Mycology, Committee, Immune system, SAN, News, Candidiasis, Civil service commission, Caspofungin, Patient, Medical device, Pharmaceutical industry, Vaccine, Mundipharma

A new treatment option for these serious infections is a much-needed addition.”

Key Points: 
  • A new treatment option for these serious infections is a much-needed addition.”
    “We would like to thank the CHMP for their careful consideration of the use of rezafungin.
  • This positive opinion represents an important step on the journey towards approval and brings us closer to providing clinicians with an alternative treatment option for invasive Candida infections, giving hope to patients battling this infection and their families,” said Brian Sheehan, Ph.D., Chief Scientific Officer at Mundipharma.
  • The CHMP’s positive opinion on rezafungin for the treatment of serious fungal infections, such as invasive candidiasis in adults, will be referred to the European Commission (EC), which will deliver a final decision in approximately two months.
  • Cidara Therapeutics has partnered with Mundipharma, which has commercial rights to rezafungin outside the U.S. and Japan.